SG
ABMD

Societe Generale’s Abiomed Inc ABMD Stock Holding History

Societe Generale’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		$393K Buy
+3,599
New +$358K ﹤0.01% 1833

Other funds holding ABMD

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Societe Generale's ABMD Position: Q2 2016 in Review

Societe Generale opened a new position in Abiomed Inc (ABMD) in Q2 2016: 3,599 shares worth $393K. The stake represents ﹤0.01% of the portfolio and ranks #1833 among its holdings.

297 funds tracked by Wall St. Rank hold ABMD as of Q2 2016.

  • Societe Generale held 3,599 shares of Abiomed Inc worth $393K as of Q2 2016.
  • Abiomed Inc was a new Societe Generale position in Q2 2016.
  • Abiomed Inc made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #1833 holding.
  • 297 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.